US man with genetically modified pig heart transplant dies
A 57-year-old man with terminal heart disease who made history as the first person to receive a genetically modified pig’s heart transplant died on Tuesday at the University of Maryland Medical Center (UMMC), the hospital said.
David Bennett received the transplant on Jan 7.
His condition began deteriorating several days ago, the hospital said in a statement on Wednesday, and he was given “compassionate palliative care” after it became clear that he would not recover.
Bennett “wasn’t able to overcome what turned out to be the devastating debilitation” caused by the heart failure he experienced before the transplant, Dr. Bartley Griffith, director of the UMCC cardiac transplant program, said in a videotaped statement.
The transplanted heart functioned “beautifully,” Griffith said.
Bennett was able to communicate with his family during his final hours, the hospital said.
David Bennett, a 57-year-old patient with terminal heart disease, poses with surgeon Bartley P. Griffith, MD before he received a successful transplant of a genetically-modified pig heart at University of Maryland Medical Center in Baltimore, Maryland, U.S. in an undated photograph. University of Maryland School of Medicine (UMSOM)/Handout via REUTERS.
Bennett first came to UMMC as a patient in October and was placed on a heart-lung bypass machine, but was deemed ineligible for a conventional heart transplant.
After Bennett received a pig heart that had been modified to prevent rejection with the use of new gene editing tools, his son called the procedure “a miracle.”
For Bennett, the procedure was his last option.
“Before consenting to receive the transplant, Mr Bennett was fully informed of the procedure’s risks, and that the procedure was experimental with unknown risks and benefits,” the hospital said.
Related Articles
Researchers have long considered pigs to be a potential source of organs for transplants because they are anatomically similar to humans in many ways. Prior efforts at pig-to-human transplants had failed because of genetic differences that caused organ rejection or viruses that posed an infection risk.
“The demonstration that it was possible – that we were able to take a genetically engineered organ and watch it function flawlessly for nine weeks, is pretty positive in terms of the potential for this therapy,” Griffith said.
(Reporting by Kanishka Singh in Bengaluru and Nancy Lapid in New York; Editing by Chizu Nomiyama, Bill Berkrot, Caroline Humer and Robert Birsel)
